NEXTBio Capital Management LP
NEXTBio Capital Management LP reported 22 US-listed holdings worth $217.4 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Protagonist Therapeutics, Inc. (12.4%), Shattuck Labs Inc. (11.9%) and Compass Pathways PLC (11.6%). Against the quarter before, it opened 3 positions, added to 7, trimmed 4 and sold out of 5.
The 14 largest of its 22 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +28.4% over the 2 quarters to 30 June 2026, against +9.5% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 3
- Pharvaris N V PHVS$3.7 million
- Bioage Labs Inc. BIOA$2.5 million
- LB Pharmaceuticals Inc. LBRX$2.2 million
Added to 7
- Structure Therapeutics Inc. GPCR+179,257 shares · +135%
- Shattuck Labs Inc. STTK+577,441 shares · +18%
- Oric Pharmaceuticals Inc. ORIC+182,505 shares · +35%
- Inventiva SA IVA+454,500 shares · +34%
- Palvella Therapeutics Inc. Ne PVLA+7,223 shares · +9%
- Vaxcyte Inc. PCVX+12,000 shares · +13%
- Rhythm Pharmaceuticals Inc. RYTM+5,680 shares · +5%
Trimmed 4
- Compass Pathways PLC CMPS-245,648 shares · -12%
- Vor Biopharma Inc. VOR-110,803 shares · -11%
- Protagonist Therapeutics, Inc. PTGX-10,286 shares · -4%
- Evommune Inc. EVMN-65,000 shares · -35%
Sold out of 5
- Terns Pharmaceuticals Inc. TERN$31.9 million last quarter
- Compass Therapeutics Inc. CMPX$4.5 million last quarter
- Oculis Holding AG OCS$4.0 million last quarter
- Kalvista Pharmaceuticals Inc. KALV$2.7 million last quarter
- Summit Therapeutics Inc. SMMT$1.7 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Protagonist Therapeutics, Inc. PTGX | 219.3K | $26.9 million | 12.37% | -10.3K |
| Shattuck Labs Inc. STTK | 3.7M | $25.9 million | 11.90% | +577.4K |
| Compass Pathways PLC CMPS | 1.8M | $25.1 million | 11.56% | -245.6K |
| Structure Therapeutics Inc. GPCR | 312.5K | $16.8 million | 7.71% | +179.3K |
| Vor Biopharma Inc. VOR | 889.2K | $16.4 million | 7.53% | -110.8K |
| Rhythm Pharmaceuticals Inc. RYTM | 131.8K | $14.6 million | 6.73% | +5.7K |
| Palvella Therapeutics Inc. Ne PVLA | 89.9K | $13.7 million | 6.32% | +7.2K |
| Xenon Pharmaceuticals Inc. XENE | 183.2K | $11.1 million | 5.09% | no change |
| Zenas Biopharma Inc. ZBIO | 426.7K | $10.8 million | 4.98% | no change |
| Oric Pharmaceuticals Inc. ORIC | 706.1K | $7.6 million | 3.52% | +182.5K |
| Inventiva SA IVA | 1.8M | $6.8 million | 3.11% | +454.5K |
| Crescent Biopharma Inc. CBIO | 372.9K | $6.7 million | 3.09% | no change |
| Vaxcyte Inc. PCVX | 107.2K | $6.2 million | 2.87% | +12.0K |
| Cogent Biosciences Inc. COGT | 131.1K | $5.1 million | 2.33% | -113 |
| Verastem Inc. VSTM | 1.3M | $5.0 million | 2.30% | no change |
| Disc Medicine Inc. IRON | 52.7K | $3.9 million | 1.77% | no change |
| Pharvaris N V PHVS | 108.1K | $3.7 million | 1.72% | new |
| Zai Lab Limited ZLAB | 183.4K | $3.5 million | 1.60% | no change |
| Bioage Labs Inc. BIOA | 100.7K | $2.5 million | 1.14% | new |
| LB Pharmaceuticals Inc. LBRX | 68.2K | $2.2 million | 1.02% | new |
| Evommune Inc. EVMN | 119.1K | $1.6 million | 0.73% | -65.0K |
| Adicet Bio Inc. ACET | 157.8K | $1.4 million | 0.63% | no change |